JPMorgan Chase & Co. Has Lowered Expectations for Moderna (NASDAQ:MRNA) Stock Price

Moderna (NASDAQ:MRNA) had its target price reduced by JPMorgan Chase & Co. from $59.00 to $45.00 in a research report sent to investors on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an underweight rating on the stock.

Other analysts have also issued reports about the stock. Leerink Partners decreased their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and decreased their target price for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Wolfe Research began coverage on shares of Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. The Goldman Sachs Group decreased their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Finally, TD Cowen decreased their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $83.33.

Moderna Stock Performance

NASDAQ MRNA opened at $43.06 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm has a market capitalization of $16.57 billion, a price-to-earnings ratio of -7.40 and a beta of 1.69. The company’s fifty day moving average is $52.38 and its two-hundred day moving average is $91.36. Moderna has a 52-week low of $35.80 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the business posted ($1.39) EPS. Equities research analysts forecast that Moderna will post -9.44 EPS for the current year.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 1,147 shares of company stock valued at $76,245. Insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

A number of institutional investors and hedge funds have recently modified their holdings of the business. Commerzbank Aktiengesellschaft FI raised its stake in shares of Moderna by 1.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after buying an additional 93 shares during the last quarter. CVA Family Office LLC raised its stake in shares of Moderna by 21.6% during the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after buying an additional 96 shares during the last quarter. Claro Advisors LLC raised its stake in shares of Moderna by 2.0% during the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after buying an additional 108 shares during the last quarter. McAdam LLC raised its stake in shares of Moderna by 1.1% during the second quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after buying an additional 117 shares during the last quarter. Finally, 180 Wealth Advisors LLC raised its stake in shares of Moderna by 1.1% during the second quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after buying an additional 160 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.